Neptune Technologies & Bioresources Inc (NEPT) 1.83 $NEPT
NeuroBioPharm's Shareholders Approve Arrangement With Neptune
GlobeNewswire - Thu Feb 12, 1:28PM CST
NeuroBioPharm Inc. ("NeuroBio"
, a subsidiary of Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB), announces that its shareholders (the "Shareholders" approved a resolution today authorizing the previously announced plan of arrangement (the "Arrangement" providing for, among other things, the indirect acquisition by Neptune of all of the issued and outstanding shares of NeuroBio.
NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
Should Neptune Technologies & Bioressources (NEPT) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 8:00AM CST
Neptune Technologies & Bioressources has been overlooked by investors but it has actually seen estimates rise over the past month.
NEPT: 1.83 (+0.06)
Dr. Tina Sampalis Appointed Medical Science Liaison for Neptune
GlobeNewswire - Thu Feb 05, 6:28AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), announce the transition of Dr. Tina Sampalis from Chief Global Strategic Officer to a consulting role as Medical Science Liaison for Neptune, starting immediately.
ACST: 0.44 (unch), NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06), APO.VN: 0.530 (-0.020)
Jim Hamilton Officially Starts at Neptune
GlobeNewswire - Tue Feb 03, 12:34PM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB), announces that on February 2, 2015 Mr. Jim Hamilton officially started as Neptune's President and CEO.
NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
Neptune's (NEPT) CEO André Godin on Q3 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 15, 8:59AM CST
NEPT: 1.83 (+0.06)
Neptune Technologies & Bioressources ups earnings by 101% in FQ3
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 7:17AM CST
NEPT: 1.83 (+0.06)
Neptune Technologies misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 4:15PM CST
NEPT: 1.83 (+0.06)
Neptune Announces Third Quarter Results
GlobeNewswire - Tue Jan 13, 4:05PM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB), announces its consolidated financial results for the three and nine month periods ended November 30, 2014.
NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
NeuroBioPharm to be Privatized by Neptune - Enters Into Arrangement Agreement With Neptune and Obtains Interim Order
GlobeNewswire - Tue Jan 13, 4:04PM CST
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and NeuroBioPharm Inc. ("NeuroBio" , a subsidiary of Neptune, announce that they have entered into an arrangement agreement (the "Arrangement Agreement" which will result in the indirect acquisition by Neptune of all of the issued and outstanding shares of NeuroBio. The Arrangement Agreement provides, amongst other things, that NeuroBio will amalgamate with a newly formed wholly-owned subsidiary of Neptune and that each shareholder of NeuroBio will receive, as applicable, (i) 0.046296296 share of Neptune for each Class A share of NeuroBio held, (ii) 0.185185185 share of Neptune for each Class B share of NeuroBio held, (iii) 0.092592593 share of Neptune for each Class G share of NeuroBio held, and (iv) 0.208333333 share of Neptune for each Class H share of NeuroBio held (the "Arrangement" . Holders of options, warrants or call options convertible into Class A shares of NeuroBio will maintain equivalent rights to receive common shares of Neptune upon exercise, as adjusted under the Arrangement to reflect the conversion ratio of the Class A shares of NeuroBio.
NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
5 Earnings Short-Squeeze Plays: Neptune Technologies and More
at The Street - Tue Jan 13, 5:00AM CST
You only need to find a few of these stocks in a year to help enhance your portfolio returns.
FAST: 42.50 (+0.26), WABC: 43.59 (+0.47), LLTC: 48.38 (+0.45), NEPT: 1.83 (+0.06), CLC: 65.68 (+0.32)
Neptune to Present at OneMedForum
GlobeNewswire - Thu Jan 08, 6:12AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company" (Nasdaq:NEPT) (TSX:NTB) announces that Andre Godin, Neptune's Interim President and Chief Executive Officer, will provide a business overview at the OneMedForum 2015 Investor Conference on Tuesday, January 13, 2015 at 3:15 p.m. PST (6:15 ET). The Conference is being held at the Marriott Marquis Hotel in San Francisco, California.
NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
Neptune reports January 13
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 7:13AM CST
NEPT: 1.83 (+0.06)
Neptune to Hold Conference Call to Discuss Third Quarter Results
GlobeNewswire - Tue Jan 06, 6:00AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB), announced today that it will be holding a conference call on Wednesday January 14, 2015 at 9:00 AM (ET) to present its results for the third quarter ended November 30, 2014. The third quarter results press release will be issued after markets close on January 13, 2015.
NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
Rolling With Biotech's Regulatory Punches: Chen Lin
Life Sciences Report - Seeking Alpha - Tue Nov 25, 3:36PM CST
Being temporarily burned by the U.S. Food and Drug Administration can be a mixed blessing for a biotech with a good product in the pipeline. In an interview with The Life Sciences Report , Chen Lin, publisher of the investor newsletter What is...
ACRX: 7.29 (-0.06), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99), SRNE: 11.41 (+0.56), NEPT: 1.83 (+0.06), CELG: 115.88 (+0.16)
New Chief at Neptune
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 6:38AM CST
NEPT: 1.83 (+0.06)
Jim Hamilton Appointed President & CEO of Neptune
GlobeNewswire - Fri Nov 21, 7:07AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB), announces that its Board of Directors has appointed Jim Hamilton as President and Chief Executive Officer of Neptune and a member of the Board, effective February 2, 2015.
NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
9 Insiders Purchase Shares Of Neptune On The Open Market
D. Mero - Seeking Alpha - Tue Nov 18, 1:37PM CST
After the market closed on Friday, November 14th, Canadian Insider disclosed that 9 insiders purchased shares of Neptune Technologies (NASDAQ: NEPT ) in the open market during the past week, including the company's interim CEO, Andre Godin, and new...
NEPT: 1.83 (+0.06)
Neptune Completes Plant Ramp-Up
GlobeNewswire - Wed Nov 05, 7:07AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB), announces that its Sherbrooke plant ramp-up is successfully completed, with the plant now operating at an annualized production capacity of 150 metric tons.
NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
Neptune Receives TSX Approval for Normal Course Issuer Bid
GlobeNewswire - Thu Oct 30, 7:01AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB) announces that it has received approval of the Toronto Stock Exchange (''TSX'' to proceed with its normal course issuer bid ("NCIB" announced on October 15, 2014.
NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
NeuroBioPharm's Shareholders Approve Arrangement With Neptune
GlobeNewswire - Thu Feb 12, 1:28PM CST
NeuroBioPharm Inc. ("NeuroBio"
, a subsidiary of Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB), announces that its shareholders (the "Shareholders" approved a resolution today authorizing the previously announced plan of arrangement (the "Arrangement" providing for, among other things, the indirect acquisition by Neptune of all of the issued and outstanding shares of NeuroBio. NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
Should Neptune Technologies & Bioressources (NEPT) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 8:00AM CST
Neptune Technologies & Bioressources has been overlooked by investors but it has actually seen estimates rise over the past month.
NEPT: 1.83 (+0.06)
Dr. Tina Sampalis Appointed Medical Science Liaison for Neptune
GlobeNewswire - Thu Feb 05, 6:28AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), announce the transition of Dr. Tina Sampalis from Chief Global Strategic Officer to a consulting role as Medical Science Liaison for Neptune, starting immediately. ACST: 0.44 (unch), NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06), APO.VN: 0.530 (-0.020)
Jim Hamilton Officially Starts at Neptune
GlobeNewswire - Tue Feb 03, 12:34PM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announces that on February 2, 2015 Mr. Jim Hamilton officially started as Neptune's President and CEO. NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
Neptune's (NEPT) CEO André Godin on Q3 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 15, 8:59AM CST
NEPT: 1.83 (+0.06)
Neptune Technologies & Bioressources ups earnings by 101% in FQ3
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 7:17AM CST
NEPT: 1.83 (+0.06)
Neptune Technologies misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 4:15PM CST
NEPT: 1.83 (+0.06)
Neptune Announces Third Quarter Results
GlobeNewswire - Tue Jan 13, 4:05PM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announces its consolidated financial results for the three and nine month periods ended November 30, 2014. NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
NeuroBioPharm to be Privatized by Neptune - Enters Into Arrangement Agreement With Neptune and Obtains Interim Order
GlobeNewswire - Tue Jan 13, 4:04PM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and NeuroBioPharm Inc. ("NeuroBio" , a subsidiary of Neptune, announce that they have entered into an arrangement agreement (the "Arrangement Agreement" which will result in the indirect acquisition by Neptune of all of the issued and outstanding shares of NeuroBio. The Arrangement Agreement provides, amongst other things, that NeuroBio will amalgamate with a newly formed wholly-owned subsidiary of Neptune and that each shareholder of NeuroBio will receive, as applicable, (i) 0.046296296 share of Neptune for each Class A share of NeuroBio held, (ii) 0.185185185 share of Neptune for each Class B share of NeuroBio held, (iii) 0.092592593 share of Neptune for each Class G share of NeuroBio held, and (iv) 0.208333333 share of Neptune for each Class H share of NeuroBio held (the "Arrangement" . Holders of options, warrants or call options convertible into Class A shares of NeuroBio will maintain equivalent rights to receive common shares of Neptune upon exercise, as adjusted under the Arrangement to reflect the conversion ratio of the Class A shares of NeuroBio. NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
5 Earnings Short-Squeeze Plays: Neptune Technologies and More
at The Street - Tue Jan 13, 5:00AM CST
You only need to find a few of these stocks in a year to help enhance your portfolio returns.
FAST: 42.50 (+0.26), WABC: 43.59 (+0.47), LLTC: 48.38 (+0.45), NEPT: 1.83 (+0.06), CLC: 65.68 (+0.32)
Neptune to Present at OneMedForum
GlobeNewswire - Thu Jan 08, 6:12AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company"
(Nasdaq:NEPT) (TSX:NTB) announces that Andre Godin, Neptune's Interim President and Chief Executive Officer, will provide a business overview at the OneMedForum 2015 Investor Conference on Tuesday, January 13, 2015 at 3:15 p.m. PST (6:15 ET). The Conference is being held at the Marriott Marquis Hotel in San Francisco, California. NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
Neptune reports January 13
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 7:13AM CST
NEPT: 1.83 (+0.06)
Neptune to Hold Conference Call to Discuss Third Quarter Results
GlobeNewswire - Tue Jan 06, 6:00AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announced today that it will be holding a conference call on Wednesday January 14, 2015 at 9:00 AM (ET) to present its results for the third quarter ended November 30, 2014. The third quarter results press release will be issued after markets close on January 13, 2015. NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
Rolling With Biotech's Regulatory Punches: Chen Lin
Life Sciences Report - Seeking Alpha - Tue Nov 25, 3:36PM CST
Being temporarily burned by the U.S. Food and Drug Administration can be a mixed blessing for a biotech with a good product in the pipeline. In an interview with The Life Sciences Report , Chen Lin, publisher of the investor newsletter What is...
ACRX: 7.29 (-0.06), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99), SRNE: 11.41 (+0.56), NEPT: 1.83 (+0.06), CELG: 115.88 (+0.16)
New Chief at Neptune
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 6:38AM CST
NEPT: 1.83 (+0.06)
Jim Hamilton Appointed President & CEO of Neptune
GlobeNewswire - Fri Nov 21, 7:07AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announces that its Board of Directors has appointed Jim Hamilton as President and Chief Executive Officer of Neptune and a member of the Board, effective February 2, 2015. NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
9 Insiders Purchase Shares Of Neptune On The Open Market
D. Mero - Seeking Alpha - Tue Nov 18, 1:37PM CST
After the market closed on Friday, November 14th, Canadian Insider disclosed that 9 insiders purchased shares of Neptune Technologies (NASDAQ: NEPT ) in the open market during the past week, including the company's interim CEO, Andre Godin, and new...
NEPT: 1.83 (+0.06)
Neptune Completes Plant Ramp-Up
GlobeNewswire - Wed Nov 05, 7:07AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announces that its Sherbrooke plant ramp-up is successfully completed, with the plant now operating at an annualized production capacity of 150 metric tons. NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
Neptune Receives TSX Approval for Normal Course Issuer Bid
GlobeNewswire - Thu Oct 30, 7:01AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB) announces that it has received approval of the Toronto Stock Exchange (''TSX'' to proceed with its normal course issuer bid ("NCIB" announced on October 15, 2014. NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06)
